FINOX AG Company Profile
FINOX pioneers niche Biosimilars and wants to establish itself as a respected competitor in these markets.
Through our Biosimilars to come we aim to create value for patients, partners and the investors:
* for patients - with safe, efficient, easy-to-apply and fair priced therapies of highest quality
* for partners and investors - with transparent partnerships of mutual benefit
Within a network of specialised partners we develop our Biosimilars from molecule to market.
Location
Technikumstrasse 2
Burgdorf
3401
Switzerland
Contact
Phone: +41 (0)34 424 30 60
Fax: +41 (0)34 424 30 55
Email: info@finox.ch
News Articles
Finox submits r-FSH biosimilar MAA to EMA
FINOX Biotech has submitted the Marketing Authorisation Application (MAA) for its biosimilar recombinant Follicle Stimulating Hormone (r-FSH) BEMFOLA to the European Medicines Agency.
Finox submits r-FSH biosimilar application to EMA
Finox Biotech announced on 20 December 2012 that it had submitted a Marketing Authorisation Application (MAA) for its biosimilar recombinant follicle stimulating hormone (r-FSH) to EMA on 30 October 2...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
FINOX pioneers niche Biosimilars and wants to establish itself as a respected competitor in these markets. Through our Biosimilars to come we aim to create value for patients, partners and the inve...
More Information about "FINOX AG" on BioPortfolio
We have published hundreds of FINOX AG news stories on BioPortfolio along with dozens of FINOX AG Clinical Trials and PubMed Articles about FINOX AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FINOX AG Companies in our database. You can also find out about relevant FINOX AG Drugs and Medications on this site too.
